ADB-BUTINACA is classified as a synthetic cannabinoid drug used mainly in study to study its psychoactive properties, receptor interactions, and potential therapeutic purposes. ADB – Butinaca can be a managed compound additional to Agenda II in 2023, demonstrating it’s watched closely